Volition Announces Clinical Research Study with Oncovet

Volition Announces Clinical Research Study with Oncovet

HENDERSON, Nev., Nov. 14, 2022 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-countrywide epigenetics company, has announced a medical investigate examine with Oncovet, a renowned veterinary referral clinic, specializing in health care and radiation oncology.

The non-interventional research is remaining led by Dr. Jérôme Benoit, Oncovet’s Scientific Director, and will assess circulating nucleosomes of puppies and cats with cancer using Volition’s Nu.Q® Vet Most cancers Exam.

Volition’s Nu.Q® Vet Cancer Examination is a uncomplicated, uncomplicated-to-use blood take a look at currently out there for most cancers screening in canines with ongoing investigate into its use for cancer screening in cats, and ailment checking in both equally species.

Dr. Jérôme Benoit, Clinical Director at Oncovet, claimed: “Volition’s Nu.Q® Vet Cancer Examination has presently been proven to detect systemic cancers in pet dogs this sort of as lymphoma and hemangiosarcoma. We will seek to establish irrespective of whether other typical cancers that we on a regular basis see in clinic, could also be detected in pet dogs and cats by measuring circulating nucleosomes at prognosis and in the course of procedure.

“We are enthusiastic to function with the group at Volition, giving samples from 100 canine and 25 cats with a vast assortment of cancers, about the coming year. We glimpse forward to supporting Volition as the corporation expands its functions into Europe, enabling veterinarians and pet proprietors throughout the location to benefit from the Nu.Q® Vet Cancer Take a look at.”

Dr. Tom Butera, Main Government Officer of Volition Veterinary Diagnostics Growth LLC, said: “We are delighted to collaborate with Dr. Benoit and his group on this analysis research. Jérôme is very highly regarded within the veterinary oncology sector and Oncovet is very well recognized in Europe for the style and design and management of veterinary medical trials in pet dogs and cats.”

“We are hoping that this first study will be the get started of an successful, extensive-time period marriage with Oncovet, as we search for to broaden the vary of cancers that our Nu.Q® Vet Cancer Test can detect throughout diverse species. We glance ahead to sharing the final results.”

Volition is building very simple, effortless-to-use, cost-helpful blood checks to help diagnose and keep an eye on a range of lifetime-altering illnesses which includes most cancers in each individuals and animals. For extra data about Volition’s Nu.Q® technological innovation go to: www.volition.com.

Observe to editors:

Conclusions from a clinical research carried out by Volition and Professor Wilson-Robles and the staff at Texas A&M University, peer-reviewed and posted in August 2022, confirmed that:

About Volition

Volition is a multi-countrywide epigenetics company that applies its Nucleosomics™ system by way of its subsidiaries to build straightforward, quick to use, value successful blood exams to aid diagnose and watch a array of everyday living-altering health conditions including some cancers and illnesses connected with NETosis this kind of as sepsis and COVID-19. Early prognosis and monitoring have the opportunity not only to lengthen the life of patients but also to increase their quality of daily life. The exams are primarily based on the science of Nucleosomics™, which is the follow of pinpointing and measuring nucleosomes in the bloodstream or other bodily fluid – an sign that disease is existing.

Volition’s research and progress pursuits are centered in Belgium, with an innovation laboratory and business office in the U.S. and further places of work in London and Singapore.

The contents uncovered at Volition’s and Oncovet’s web page addresses are not included by reference into this document and should not be regarded as element of this doc.  Such website addresses are involved in this document as inactive textual references only.

About Oncovet

Oncovet’s mission is to give the greatest possible welcome and cure to the clients you entrust us with. Oncovet strives for excellence and relies on the expertise of its professionals renowned at European stage, as nicely as on the staff supporting them, to present thorough care. Our services consist of medical procedures, cardiology, imaging, radiotherapy, healthcare oncology, and inside drugs. We care for individuals who appear to us from throughout Europe. For more facts, go to: www.oncovet.fr

Volition Enquiries:

Louise Batchelor/Debra Daglish, Volition, [email protected] +44 ()7557 774620

Safe and sound Harbor Assertion

Statements in this press launch could be “forward-hunting statements” within just the that means of Area 27A of the Securities Act of 1933, as amended, and Portion 21E of the Securities Trade Act of 1934, as amended, that concern issues that involve risks and uncertainties that could induce genuine benefits to vary materially from individuals predicted or projected in the forward-looking statements. Words these kinds of as “expects,” “anticipates,” “intends,” “ideas,” “aims,” “targets,” “thinks,” “seeks,” “estimates,” “optimizing,” “opportunity,” “objective,” “implies,” “could,” “would,” “really should,” “may,” “will” and related expressions detect forward-seeking statements. These forward-on the lookout statements relate to, amid other subjects, Volition’s anticipations similar to the probable utilizes, benefits and performance of its Nucleosomics™ engineering system, which include the Nu.Q® Vet Cancer Check, as properly as the expected benefits of its partnership with Oncovet. Volition’s real outcomes could differ materially from those people indicated in these ahead-hunting statements due to several hazards and uncertainties, which includes, devoid of limitation, benefits of scientific studies screening the efficacy of its assessments, a failure by the market to accept Volition’s Nu.Q® Vet Cancer Test or other solutions based mostly on its Nucleosomics™ platform Volition’s failure to secure ample intellectual property protection Volition’s failure to obtain important regulatory clearances or approvals to distribute and market potential products Volition will facial area fierce competitors and its supposed goods may perhaps turn out to be obsolete thanks to the extremely aggressive character of the diagnostics and condition monitoring marketplaces and their speedy technological alter downturns in domestic and foreign economies and other pitfalls, like those people identified in Volition’s most recent Once-a-year Report on Form 10-K and Quarterly Experiences on Form 10-Q, as nicely as other paperwork that Volition data files with the Securities and Exchange Fee. For occasion, if Volition fails to develop and commercialize diagnostic, prognostic or illness checking solutions, it may perhaps be unable to execute its system of functions. Ahead-hunting statements are based on present anticipations, estimates and projections about Volition’s business based, in aspect, on assumptions manufactured by management. These statements are not assures of long run performance and include challenges, uncertainties and assumptions that are hard to forecast. Ahead-searching statements are created as of the day of this release, and, besides as expected by legislation, Volition does not undertake an obligation to update its forward-wanting statements to mirror foreseeable future gatherings or circumstances.

Nucleosomics™ and Nu.Q® and their respective logos are logos and/or company marks of VolitionRx Restricted and its subsidiaries.  All other logos, assistance marks and trade names referred to in this push launch are the house of their respective homeowners.



Watch unique content material:https://www.prnewswire.com/news-releases/volition-announces-clinical-investigate-analyze-with-oncovet-301676933.html

Resource VolitionRx